News & Events
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894, CRN04777 and its other research and development programs, and for working capital and general corporate purposes. SVB Leerink, Evercore ISI and Cantor are acting as joint bookrunning managers for the offering. H.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics.
READ MORERadionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
Radionetics’ pipeline is based on a broadly enabling platform and intellectual property that will leverage more than a decade of discovery experience within Crinetics. The platform uses nonpeptides as targeting agents designed to deliver therapeutically active radiopharmaceuticals to tumors expressing unique peptide receptors. Radionetics’ initial drug development efforts will center on advancing a collection of 10 potent nonpeptide-targeted radiopharmaceutical candidates and leads, discovered at Crinetics, into clinical imaging and efficacy studies.
READ MORECrinetics Pharmaceuticals Unveils Parathyroid Hormone Receptor Antagonist Program at ASBMR
“Our PTHR1 antagonists have the potential to improve the lives of people with hypercalcemia caused by parathyroid adenomas; and moreover, may offer a life-saving treatment option for patients with CKD or cancer, for whom hypercalcemia is a complication that can be fatal. We look forward to the continued advancement of this preclinical program and to the identification of a lead PTHR1 antagonist for optimization. ” - Alan Krasner, M.
READ MORECRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
Alan Krasner, M. D. , chief medical officer at Crinetics, added, “We are very encouraged by these single ascending dose data that clearly demonstrate proof-of-SST5 agonism and resultant inhibition of insulin secretion with CRN04777 exposure in healthy volunteers.
READ MORECrinetics Pharmaceuticals to Participate in September Investor Conferences
Crinetics' management will be participating in investor conferences hosted by H. C. Wainwright, SVB Leerink and Cantor Fitzgerald during the month of September.
READ MORECrinetics Appoints Jeff Knight as Chief Operating Officer
“Jeff’s intellectual curiosity and proven ability to grow into new roles makes him a natural fit for the Crinetics team. We look forward to applying his specific expertise in operational and clinical management as we continue to advance our pipeline and increase the staff and infrastructure necessary to support the growing clinical and commercial operations. ” - Scott Struthers, Ph.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
